Benitec Biopharma Q3 2024 GAAP EPS $(1.64) Misses $(0.78) Estimate
Portfolio Pulse from Benzinga Newsdesk
Benitec Biopharma reported a Q3 2024 GAAP EPS loss of $(1.64), missing the consensus estimate of $(0.78) by 110.26%.
May 13, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Benitec Biopharma's Q3 2024 earnings missed analyst estimates by a significant margin, reporting a loss of $(1.64) per share against the expected $(0.78).
Missing earnings estimates by a wide margin typically leads to negative investor sentiment and can result in a decrease in stock price in the short term. The significant miss in earnings per share (EPS) suggests operational or financial challenges that could concern investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100